Mod­er­na's glo­be­trot­ting BD team snags an mR­NA up­start with some handy new tech tools

Mod­er­na CEO Stéphane Ban­cel made it clear ear­ly on in their M&A map­ping phase that the biotech would be hunt­ing the world for just the right mR­NA-re­lat­ed deals to build the com­pa­ny in­to a glob­al pow­er­house. And noth­ing il­lus­trates that strat­e­gy bet­ter than the $85 mil­lion tuck-in that the biotech is un­veil­ing this morn­ing.

Ban­cel has struck a deal to buy Tokyo-based Ori­Ciro Ge­nomics and its work on cell-free syn­the­sis and am­pli­fi­ca­tion of plas­mid DNA, build­ing up their set of tech for man­u­fac­tur­ing aimed at scal­ing up pro­duc­tion faster and carv­ing weeks out of the process.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER